IFNA1 and cancer: This is the first study to report that apigenin at physiologically achievable concentrations (1–20 μM) can activate the type I IFN-induced JAK/STAT pathway and increase the endogenous IFN-regulated gene expression, resulting in the sensitization of cancer cells to the anti-cell viability effect of type I IFNs.